The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

Discover how recent advancements in ejaculation-preserving techniques during HoLEP have yielded encouraging results.

While Rybelsus is not a weight loss medication, the same study saw participants weighing over 200 pounds lose an average of 5 to 8 pounds. Common side effects include nausea, stomach pain ...

After hours: January 28 at 6:45:24 PM EST Loading Chart for AOSL ...

Only about 5% of people with type 2 diabetes will achieve remission. A new study has found a combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet provides higher rates ...

Cassidy Horton is a finance writer covering banking, life insurance and business loans. She has worked with top finance brands including NerdWallet, MarketWatch and Consumer Affairs. Cassidy first ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor ... is a clutch of drugs in mid-stage development, including Immutep's soluble LAG-3 protein eftilagimod alpha, Novartis ...

(NASDAQ:DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for ... pharmaceutical service on Seeking Alpha Marketplace. If you like what you read ...

Dolutegravir is not an inducer or inhibitor of CYP450 or uridine diphosphate glucuronosyltransferase enzymes and therefore is associated with few drug interactions other than metformin and dofetilide.

They describe the strength of evidence as compelling, highlighting the therapeutic potential of maintaining CDK4/6 inhibitor treatment when combating drug-resistant breast cancer. They also highlight ...